Astria Therapeutics, Inc.

Report azionario NasdaqGM:ATXS

Capitalizzazione di mercato: US$718.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Astria Therapeutics Dividendi e riacquisti

Criteri Dividendo verificati 0/6

Astria Therapeutics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-0.0004%

Rendimento del riacquisto

Rendimento totale per gli azionisti-0.0004%
Rendimento futuro dei dividendin/a
Crescita dei dividendin/a
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Rapporto di remunerazionen/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Seeking Alpha • Nov 30

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Summary I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks. While deal risks exist, they are considered minimal; with limited upside from current prices, I have exited my existing position. Read the full article on Seeking Alpha
Articolo di analisi • Jul 08

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Articolo di analisi • Mar 13

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 18

Astria Therapeutics: A High-Conviction Bet On HAE

Summary Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation. Astria's strategic focus on patient-centric dosing regimens and regulatory strength could reshape treatment landscapes, but clinical and commercial execution remains crucial for success. Read the full article on Seeking Alpha
Seeking Alpha • Nov 27

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Summary Astria Therapeutics, Inc.'s STAR-0215 shows 90-96% reduction in HAE attack frequency, with a twice-a-year dosing regimen, positioning it as a transformative therapy. The company has a strong cash balance of $344 million, ensuring a runway until 2027, supporting continued development and trials. Competitive positioning is strong, with STAR-0215 outperforming existing treatments like Takhzyro and Haegarda in both efficacy and dosing convenience. Risks are minimal given the promising data, making ATXS stock a buy due to its excellent data, market potential, and upcoming catalysts. Read the full article on Seeking Alpha
Articolo di analisi • Nov 14

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Astria Therapeutics...
Articolo di analisi • Jul 11

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 24

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Summary Astria Therapeutics stock has fallen 40% since early 2023, but promising early data for its candidate STAR-0215 in treating HAE is helping drive analyst Buy ratings. ATXS stock has a compound called STAR-0310 in development for an immune disorder, with plans for a Phase 1a study in 2025. Despite positive early data for STAR-0215, competition in the HAE market is fierce and likely to get more crowded with promising new treatments on the horizon. An updated analysis of Astria Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 04

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Summary Astria Therapeutics (formerly Catabasis Pharmaceuticals) acquired Quellis Biosciences and its lead program, STAR-0215, for the treatment of hereditary angioedema (HAE) in 2021. The company has successfully completed a Phase 1 study for STAR-0215, demonstrating positive results in terms of safety, tolerability, and efficacy. Astria is now moving forward with a Phase 1b/2 study to establish proof-of-concept for STAR-0215 in HAE patients, with initial results expected in Q1 2024. The promise of HAE data in Q124 appears to have lifted the share price and allowed the company to raise funds. If the promise of upcoming is already baked into the share price, given how far behind the competition Astria is in HAE, and in atopic dermatitis with a second candidate, I would give its stock a "sell" rating. Read the full article on Seeking Alpha
Articolo di analisi • Dec 10

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Articolo di analisi • Jul 27

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, Astria Therapeutics...
Articolo di analisi • Apr 03

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Articolo di analisi • Nov 30

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Aug 01

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jul 15

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Astria Therapeutics (NASDAQ:ATXS) names more than 20 years of clinical development experience in rare diseases and other indications Chris Morabito, M.D., as Chief Medical Officer.  Dr. Morabito most recently served as the Chief Medical Officer at Fulcrum Therapeutics.
Seeking Alpha • Jun 30

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

After edasalonexent's failure last year, Catabasis Pharmaceuticals pivoted to the HAE market through the acquisition of Quellis Biosciences. The acquisition brought QLS-215, a preclinical stage monoclonal antibody with a potentially improved profile compared to prophylactic market leader Takhzyro. Much longer half-life and increased potency could result in less frequent administration and it could also improve efficacy. The HAE market is increasingly competitive with additional promising therapies in development, but if preclinical data of QLS-215 translate well into humans, Catabasis could deliver significant gains in the following years.

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di ATXS siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di ATXS siano aumentati.

Rendimento dei dividendi rispetto al mercato

Astria Therapeutics Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di ATXS rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (ATXS)n/a
Fondo del 25% del mercato (US)1.3%
Top 25% del mercato (US)4.0%
Media del settore (Biotechs)1.9%
Analista previsionale (ATXS) (fino a 3 anni)n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di ATXS rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di ATXS rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di ATXS per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché ATXS non ha segnalato alcun pagamento.

Scoprire le società che pagano dividendi forti

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/01/27 11:54
Prezzo dell'azione a fine giornata2026/01/22 00:00
Utili2025/09/30
Utili annuali2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Astria Therapeutics, Inc. è coperta da 1 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jonathan WollebenCitizens JMP Securities, LLC